Published 3 years ago • loading... • Updated 3 years ago

Response to neoadjuvant chemo for breast cancer varies by sex

Summary by Ground News

Both proportions and odds of pathologic complete response (pCR) to neoadjuvant chemotherapy are numerically lower. The analysis included 385 men and 68,065 women with BC treated with NAC. Women had twice the odds of pCR than men with BC (adjusted odds ratio, 2.0)

2 Articles

All

Left

Center

Right

HealthDay

Center

Response to Neoadjuvant Chemo for Breast Cancer Varies by Sex

THURSDAY, Oct. 6, 2022 (HealthDay News) -- Both proportions and odds of pathologic complete response (pCR) to neoadjuvant chemotherapy (NAC) are numerically lower in men with breast cancer (BC) versus

3 years ago

Read Full Article

Medical Xpress

Center

Response to neoadjuvant chemo for breast cancer varies by sex

Both proportions and odds of pathologic complete response (pCR) to neoadjuvant chemotherapy (NAC) are numerically lower in men with breast cancer (BC) versus women with BC for each tumor subtype, according to a study published online Sept. 7 in Cancer.

3 years ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right